Acceleron receives Orphan Designation from European Commission for sotatercept in pulmonary arterial hypertension (PAH)

Sotatercept is investigational reverse-remodeling agent designed to be a selective ligand trap. PULSAR phase 2 trial of use as part of combination therapy led to improvement in pulmonary vascular resistance (primary endpoint) and 6-minute walk distance (secondary endpoint).

Source:

Biospace Inc.